Health Care·Pharmaceuticals·$4.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.20 | N/A | -15.40% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.20 | N/A | -15.40% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions impacting performance. They did not offer specific guidance for future quarters.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in meeting EPS expectations.
Corcept Therapeutics reported earnings that fell short of expectations, particularly in EPS, which contributed to a 4.92% drop in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's near-term performance. Overall, the market reaction indicates caution as investors await more clarity on future prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN INTL GROUP
May 6, 2019